Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
The Readout

The Celgene conundrum & weighing Regeneron’s value

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan Oct. 30, 2017

Reprints
The READOUT
Alex Hogan/STAT

The Readout for October 30, 2017

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Shortage of monkeys for early-stage research jeopardizes timelines for…
Shortage of monkeys for early-stage research jeopardizes timelines for developing some drugs
Pressure is building on pharma and biotech companies to…
Pressure is building on pharma and biotech companies to take climate action
New guidelines simplify cholesterol tests: no fasting needed
New guidelines simplify cholesterol tests: no fasting needed
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories